KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Current Deferred Revenue (2016 - 2023)

Jazz Pharmaceuticals has reported Current Deferred Revenue over the past 14 years, most recently at $4000.0 for Q3 2023.

  • Quarterly Current Deferred Revenue fell 99.59% to $4000.0 in Q3 2023 from the year-ago period, while the trailing twelve-month figure was $4000.0 through Sep 2023, down 99.59% year-over-year, with the annual reading at $463000.0 for FY2022, 77.88% down from the prior year.
  • Current Deferred Revenue was $4000.0 for Q3 2023 at Jazz Pharmaceuticals, roughly flat from $4000.0 in the prior quarter.
  • Over five years, Current Deferred Revenue peaked at $8.4 million in Q1 2020 and troughed at $4000.0 in Q1 2023.
  • The 5-year median for Current Deferred Revenue is $2.5 million (2020), against an average of $3.1 million.
  • Biggest five-year swings in Current Deferred Revenue: surged 77.99% in 2020 and later tumbled 99.76% in 2023.
  • Tracing JAZZ's Current Deferred Revenue over 5 years: stood at $4.7 million in 2019, then tumbled by 46.06% to $2.5 million in 2020, then fell by 17.79% to $2.1 million in 2021, then crashed by 77.88% to $463000.0 in 2022, then crashed by 99.14% to $4000.0 in 2023.
  • According to Business Quant data, Current Deferred Revenue over the past three periods came in at $4000.0, $4000.0, and $4000.0 for Q3 2023, Q2 2023, and Q1 2023 respectively.